IUIS 2023 - Biweekly newsletter of the International Cytokine & Interferon Society

ICIS Symposium at IUIS 2023 – Novel Immuno-Biology at Single cell resolution

December 1, 2023

From Left: Musa M. Mhlanga, Collins M. Morang’a, Nada Abdel Aziz, Kondwani Jambo and Luke O’Neill at the ICIS symposium at IUIS 2023 in Cape Town [READ MORE]

Member Highlight: Meet Kathleen Mills

June 16, 2025

I’m a PhD candidate at Weill Cornell doing my dissertation research in Tobias Hohl’s lab at Memorial Sloan Kettering Cancer Center. My PhD work has focused on the role of GM-CSF in defense against the fungal pathogen Aspergillus fumigatus. Some of the best advice I’ve ever received is that it’s [READ MORE]

Photo of Amena Alrabeea in front of a waterfall

Member Highlight: Meet Amenah Alrabeea, Ph.D.

June 2, 2025

My research focuses on understanding how cytokine signaling, particularly IL-6, influences disease progression and drug resistance. I’m in the process of setting up my lab at Kuwait University, where aim to study the differences between classical and trans-signaling pathways of IL-6, and how they activate cells in distinct ways. Ultimately, [READ MORE]

Suraj Gupta, Birla Institute of Technology and Science, Pilani – Hyderabad Campus

June 2, 2025

Mr. Suraj Gupta is a fourth-year PhD Research Scholar at the Department of Pharmacy, BITS Pilani Hyderabad Campus, India, working under the supervision of Professor Sajeli Begum. His research involves the development of novel small-molecule cytokine inhibitors. A passionate medicinal chemistry enthusiast, his journey began during his B.Pharm and M.Pharm [READ MORE]

Clinical Trials, contributed by Howard A. Young

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study (INCAS)

June 1, 2025

ClinicalTrials.gov ID NCT05653193 Sponsor Manchester University NHS Foundation Trust Information provided by Manchester University NHS Foundation Trust (Responsible Party) Brief Summary This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients [READ MORE]

Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT

June 1, 2025

ClinicalTrials.gov ID NCT06130579 Sponsor Peking University People’s Hospital Information provided by Xiao-Jun Huang, Peking University People’s Hospital (Responsible Party) Brief Summary To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) [READ MORE]

Share this: